Repurposing Immunomodulatory Imide Drugs (IMiDs) in Neuropsychiatric and Neurodegenerative Disorders.
Repurposing Immunomodulatory Imide Drugs (IMiDs) in Neuropsychiatric and Neurodegenerative Disorders.
复制标题
DOI：
10.3389/fnins.2021.656921
复制
发表时间：
2021
影响因子：
4.3
通讯作者：
Greig NH
中科院分区：
文献类型：
--
作者：
Jung YJ;Tweedie D;Scerba MT;Kim DS;Palmas MF;Pisanu A;Carta AR;Greig NH
神经炎症代表主要精神疾病和神经退行性疾病的病理学和进展的共同特征。神经精神疾病已成为全球危机，影响四分之一的人，而神经系统疾病是全球老年人口的第二大死因。然而，对于大多数神经系统疾病的有效药物治疗仍然存在巨大的缺陷。事实上，对于抑郁症等疾病，安慰剂和行为疗法与抗抑郁药具有相同的效果。对于帕金森病和阿尔茨海默病等神经退行性疾病，尚未找到可以预防、减缓或治愈该疾病的药物。随着正在进行的神经系统疾病研究，出现了几种非传统的药物靶点识别途径，以满足对新颖有效治疗的需求。这些新途径之一是神经炎症，已发现神经炎症与许多主要神经系统疾病的进展和病理有关。神经炎症的特征是神经系统疾病某些阶段的神经胶质炎症因子。尽管荟萃分析提供了神经系统疾病某些阶段炎症因子的遗传/蛋白质组上调的证据。尽管支撑神经炎症和神经系统疾病之间联系的机制尚不清楚，并且荟萃分析结果显示对疾病严重程度和样本类型等因素具有高度敏感性，但有重要证据表明神经炎症与神经系统疾病之间存在关联。在这篇综述中，我们总结了神经炎症在重度抑郁症、广泛性焦虑症、创伤后应激障碍和双相情感障碍等精神疾病以及帕金森病和阿尔茨海默病等神经退行性疾病中的作用，并介绍了免疫调节酰亚胺药物（IMiD）作为这些疾病的新治疗策略的潜力的最新研究。
Neuroinflammation represents a common trait in the pathology and progression of the major psychiatric and neurodegenerative disorders. Neuropsychiatric disorders have emerged as a global crisis, affecting 1 in 4 people, while neurological disorders are the second leading cause of death in the elderly population worldwide. However, there remains an immense deficit in availability of effective drug treatments for most neurological disorders. In fact, for disorders such as depression, placebos and behavioral therapies have equal effectiveness as antidepressants. For neurodegenerative diseases such as Parkinson’s disease and Alzheimer’s disease, drugs that can prevent, slow, or cure the disease have yet to be found. Several non-traditional avenues of drug target identification have emerged with ongoing neurological disease research to meet the need for novel and efficacious treatments. Of these novel avenues is that of neuroinflammation, which has been found to be involved in the progression and pathology of many of the leading neurological disorders. Neuroinflammation is characterized by glial inflammatory factors in certain stages of neurological disorders. Although the meta-analyses have provided evidence of genetic/proteomic upregulation of inflammatory factors in certain stages of neurological disorders. Although the mechanisms underpinning the connections between neuroinflammation and neurological disorders are unclear, and meta-analysis results have shown high sensitivity to factors such as disorder severity and sample type, there is significant evidence of neuroinflammation associations across neurological disorders. In this review, we summarize the role of neuroinflammation in psychiatric disorders such as major depressive disorder, generalized anxiety disorder, post-traumatic stress disorder, and bipolar disorder, as well as in neurodegenerative disorders, such as Parkinson’s disease and Alzheimer’s disease, and introduce current research on the potential of immunomodulatory imide drugs (IMiDs) as a new treatment strategy for these disorders.
登录
查看更多内容
影响因子：
5.6
作者：
Batsaikhan, Buyandelger;Wang, Jing-Ya;Wang, Jia-Yi
通讯作者：
Wang, Jia-Yi
影响因子：
29
作者：
Baker RG;Hayden MS;Ghosh S
通讯作者：
Ghosh S
影响因子：
8.6
作者：
Barone, Paolo;Antonini, Angelo;Del Dotto, Paolo
通讯作者：
Del Dotto, Paolo
影响因子：
82.9
作者：
Baruch, Kuti;Deczkowska, Aleksandra;Schwartz, Michal
通讯作者：
Schwartz, Michal
影响因子：
4.7
作者：
Abdelsalam, Rania M.;Safar, Marwa M.
通讯作者：
Safar, Marwa M.